Shanghai Fosun Pharmaceutical : POLL RESULTS OF THE RESOLUTION PROPOSED AT THE 2019 SECOND EXTRAORDINARY GENERAL MEETING HELD ON MONDAY, 21 OCTOBER 2019

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

POLL RESULTS OF THE RESOLUTION PROPOSED AT

THE 2019 SECOND EXTRAORDINARY GENERAL MEETING

HELD ON MONDAY, 21 OCTOBER 2019

The board (the ''Board'') of directors (the ''Directors'') of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') is pleased to announce the poll results of the 2019 second extraordinary general meeting (the ''EGM'') held at Shanghai Film Art Center, No. 160 Xinhua Road, Shanghai, the People's Republic of China on Monday, 21 October at 1:30 p.m..

References are made to the notice of the EGM and the circular of the Company (the ''Circular''), both dated 3 September 2019. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the date of the EGM, (i) the total number of the issued shares of the Company (the ''Shares'') was 2,562,898,545 Shares, comprising 2,010,958,045 A Shares and 551,940,500 H Shares; and (ii) holders of 2,562,898,545 Shares (or authorized proxies) were entitled to attend and vote on the resolution proposed at the EGM. There were no Shares entitling the shareholders of the Company (the ''Shareholders'') to attend and vote only against the resolution at the EGM.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no Shareholder was required to abstain from voting at the EGM.

- 1 -

ATTENDANCE AT THE EGM

Set out below are the details of the Shareholders and authorized proxies present at the EGM:

Number of Shareholders and authorized proxies	126
Including:	Number of A Shareholders	124
	Number of H Shareholders	2
Total number of Shares carrying voting rights (shares)	1,339,607,103
Including:	Total number of Shares carrying voting rights held by	1,099,937,902
	A Shareholders
	Total number of Shares carrying voting rights held by	239,669,201
	H Shareholders
Percentage of the total number of Shares (%)	52.2692
Including:	Number of A Shares as a percentage of the number of Shares of	42.9177
	the Company
	Number of H Shares as a percentage of the number of Shares of	9.3515
	the Company

The EGM was convened in compliance with the requirements of the Company Law of the People's Republic of China and the Articles of Association, and was chaired by Mr. Chen Qiyu, the chairman of the Company.

In compliance with the requirements of the Hong Kong Listing Rules and Article 115 of the Articles of Association, BDO Limited, Grandall Law Firm (Shanghai), the Company's PRC legal advisers, Shareholder's representative and members of the supervisory committee of the Company acted as the scrutineers for the vote-counting at the EGM.

- 2 -

POLL RESULTS OF THE RESOLUTION PROPOSED AT THE EGM

The resolution at the EGM was voted by poll. The poll results in respect of the resolution proposed at the EGM are as follows:

	Ordinary Resolution	Number of valid votes (%)
	For	Against	Abstain
1.	To consider and approve the resolution in	1,321,163,595	3,558,462	14,885,046
	relation to the entering into the Transaction	(98.6232%)	(0.2656%)	(1.1112%)
	Agreement and the Rollover Agreement and
	the transactions contemplated thereunder.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2.	To consider and approve the resolution in	260,369,841	104,223,472	8,532,200
	relation to the proposed renewal of continuing	(69.7808%)	(27.9326%)	(2.2866%)
	connected transactions as contemplated under
	the Renewed Financial Services Agreement.

As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

CERTIFICATION

As certified by and stated in the legal opinion issued by Grandall Law Firm (Shanghai), the Company's PRC legal adviser, the convening and holding of the EGM are in compliance with requirements of the laws, administrative regulations, the Rules of General Meetings of Listed Companies and the Articles of Association, the qualifications of the attendees of the EGM and the convener are legally valid, and the voting procedures and voting results of the EGM are legally valid.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Chairman

Shanghai, PRC

21 October 2019

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang, Mr. Wang Can, Ms. Mu Haining and Mr. Liang Jianfeng; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

• for identification purposes only

- 3 -